Stock AnalizChemours Co CC
Major Chemicals · IPO 2015 · data as of November 13, 2026
Chemours Co (CC) is a industrial company listed in the US with a market value of about $2.0B. In the twelve months to September 30, 2026 it had revenue of $5.8B and net income of -$154M, a net margin of -2.6%.
Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is shareholder returns (5/5); the weakest is future growth (0/5).
Key numbers: a price to free cash flow of 9.5, 5-year revenue growth of 3% a year, a 5-year average ROIC of 6%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 11% above the current price.
Score: 1.6 / 5
Checks passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- Positive free cash flow
- Pays a dividend
- Share count down over 3 years (buybacks)
- 20% to 100% of free cash flow returned to shareholders
- Dividend 3 years in a row
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.8B | $5.8B | $5.8B | $6.1B | $6.8B | $6.3B | $5.0B | $5.5B | $6.6B | $6.2B |
| Net income | -$154M | -$386M | $69M | -$253M | $578M | $608M | $219M | -$52M | $995M | $746M |
| Free cash flow | $211M | $51M | -$993M | $186M | $448M | $537M | $540M | $169M | $642M | $229M |
| EPS (diluted) | $-1.02 | $-2.57 | $0.46 | $-1.70 | $3.65 | $3.60 | $1.32 | $-0.32 | $5.45 | $3.91 |
| Net margin | -2.6% | -6.7% | 1.2% | -4.2% | 8.5% | 9.6% | 4.4% | -0.9% | 15.0% | 12.1% |
| ROIC | — | -0.1% | 4.8% | -1.7% | 14.1% | 15.2% | 6.0% | 1.3% | 23.1% | 18.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 10 analysts is $16.00, 20% above the current price; targets range from $14.00 to $18.00; the consensus rating is “Hold”; expected EPS is $0.81 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Chemours Co stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 11% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Chemours Co pay a dividend?
Yes. The dividend yield is about 2.55%, and it has paid dividends for 9 years in our data.
Is Chemours Co a good stock to buy?
We do not give buy or sell advice. Chemours Co scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.